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Abstract
Background: Psoriatic arthritis (PsA) presents a unique clinical challenge. Affecting joints, skin, nails, and other
organs, it is associated with various comorbidities and has a significant impact on quality of life, social participation
and working life. While biologic and other targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs
and tsDMARDs) have revolutionised therapy, questions remain about the long-term safety of these agents, and
their effectiveness and cost-effectiveness in the real-world clinical setting.
Methods/design: The British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA) is a prospective registry
of patients with PsA, recruited from across Great Britain, who are (a) commencing a bDMARD/tsDMARD; or (b)
naïve to all bDMARDs/tsDMARDs. Ethical approval was given by the NHS West of Scotland Research Ethics
Committee 3 (reference: 18/WS/0126). Clinical data are extracted from participants’ medical records, including
symptom onset and diagnosis, joint, skin and nail symptoms, dactylitis and enthesitis. Physical measurements
(height, weight and 66/68 joint counts) and a detailed drug history are taken. Participants are also asked to
complete questionnaires comprising instruments relating to general health and quality of life, axial disease, sleep
and fatigue, impact of disease, functional status, mental health, other symptoms, and occupational status. The study
duration is 5 years in the first instance, and all participants are followed up annually until the end of the study.
Participants commencing a bDMARD/tsDMARD are also followed up three and six months after the start of therapy.
Disease activity, including C-reactive protein, is assessed at each visit; and participants from some centres are
invited to donate blood and urine samples for the creation of a biobank.
Discussion: Complementing data from randomised trials, results from this study will contribute to the evidence
base underpinning the clinical management of psoriatic arthritis. Various analyses will determine the effectiveness
and safety of bDMARDs/tsDMARDs in the real-world, will examine the clinical and biological predictors of treatment
response, and will provide real-world data on the cost-effectiveness of these therapies, as well as providing
informative data important to patients such as quality of life and occupational outcomes.
Trial registration: The full study protocol is registered on the Open Science Framework (https://osf.io/jzs8n).
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Background
Psoriatic arthritis (PsA) is an inflammatory arthritis
characterised by synovitis, enthesitis, osteitis, and skin
and nail disease. There are several phenotypes, including
oligoarticular disease, affecting only a few joints, often
unilaterally; polyarticular disease, affecting five or more
joints, bilaterally; and the severe and destructive, but less
common, arthritis mutilans. It has a significant impact
on quality of life, social participation and working life
and is associated with an increased cardiovascular risk,
likelihood of metabolic syndrome, and other important
physical and psychological comorbidities.
The advent of TNF inhibition significantly improved
outcomes for patients with PsA, and anti-TNF therapy is
now established in the management of PsA [1–5]. More
recently, other important targets have been identified
and therapies have developed apace. Accordingly, in
addition to TNF inhibitors, the rheumatologist now has
access to agents that inhibit the IL-12/23, IL-17, JAK
and PDE4 pathways, some of which have already dem-
onstrated impressive results in other rheumatological
diseases and/or psoriasis.
For many therapeutic agents, good quality long-term
data on effectiveness, cost-effectiveness, safety, and other
important outcomes in PsA are limited, and much of
what is known about the performance and safety of
these agents comes from clinical trials. Although these
data are informative, it is often collected on a narrow
subset of patients and we have shown, in axial spondy-
loarthritis, treatment response to biologic therapy in
‘real-world’ patients is significantly lower than is re-
ported in clinical trials [6]. In PsA, observational ‘real-
world’ evidence is needed, to complement data from
randomised trials. This should seek to determine the ef-
fectiveness of treatment on all aspects of phenotype, and
indeed whether treatment effectiveness varies with dis-
ease phenotype. Similarly, it is important to determine
the safety and effectiveness of therapies among patients
with the whole range of comorbidities seen in clinical
practice, especially those that would result in ineligibility
from clinical trials. Such data would allow the identifica-
tion of sub-groups of patients who may have a superior
treatment response, with participant numbers seldom
available in randomised studies. It would also create the
environment to study predictors of treatment response
that might inform future stratified approaches to patient
management.
All pharmacological interventions may be associated
with adverse side effects. Of particular relevance, im-
munosuppressive therapy is considered a potential risk
factor for both malignancy and life-threatening infection
– although, in clinical practice, these small risks are ac-
cepted if the potential patient benefit is proportionately
greater. Adverse events occurring frequently, and early
during therapy, will be ascertained during phase 2 and 3
clinical trials. However, longer-term complications such
as malignancy, rare infections, and indeed all rare events,
are unlikely to be detected until large numbers of pa-
tients have been treated and followed for a reasonable
length of time. Although much can be learned about
drug safety from other disease areas, direct extrapolation
from one disease to another may not be appropriate,
particularly where comorbidities vary between diseases.
Also, while real-world data on TNF antagonists has been
available for around 20 years, much less is known about
newer therapies: the IL-12/23, IL-17A, JAK and PDE4
inhibitors. Informed prescribing of new agents (and ar-
guably new versions of old agents) requires knowledge
of the magnitude of risk of adverse events in the longer-
term.
Here, we describe the protocol for the British Society
for Rheumatology Psoriatic Arthritis Register (BSR-PsA),
a multi-centre registry facilitating research on patients
with PsA, in secondary care in the Great Britain, who
are commencing biologic or other targeted synthetic dis-
ease modifying anti-rheumatic drugs (bDMARDs and
tsDMARDs), plus a comparison cohort of patients naïve
to bDMARD / tsDMARD therapy. It aims to provide
high quality long-term data on effectiveness, cost-
effectiveness, safety, and the impact of PsA on the indi-
vidual, including function, quality of life and social (e.g.
work) outcomes in the medium- to long-term. It also
collects the relevant data to allow robust health eco-
nomic evaluation and post-marketing surveillance of
biologic and other targeted therapies for a period beyond
that typically monitored in clinical trials.
Methods/design
Study design, population, and procedures
The BSR-PsA is a multi-centre registry of persons aged
≥16 yrs with a clinical diagnosis of PsA and who meet
the CASPAR classification criteria for PsA [7]. They are
also required to be either:
(a) Commencing a biologic, biosimilar or targeted
synthetic disease modifying anti-rheumatic drug
(bDMARD or tsDMARD) approved for the treat-
ment of PsA in the United Kingdom or part thereof,
having never previously received that particular
agent; or
(b) Naïve to all bDMARD and tsDMARD products.
Thus, the registry comprises two cohorts, considered
‘exposed’ and ‘non-exposed’ respectively. Participants are
excluded if they are unable to communicate in English;
are managed in paediatric rheumatology services; are
remaining on, or restarting, a bDMARD or tsDMARD
that they have previously received; or are unable to give
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informed consent. The registry inclusion / exclusion cri-
teria are shown in Table 1.
Potentially eligible patients with PsA are identified
from participating NHS rheumatology departments
across the UK. A list of participating centres is avail-
able from www.abdn.ac.uk/bsr-psa. Patients are sent a
participant information sheet and invitation letter
from their usual rheumatology consultant/team ahead
of their clinic appointment. Thereafter, at clinic, they
are asked whether they wish to participate. Recruit-
ment is supported in England by the National Insti-
tute for Health Research (NIHR) Clinical Research
Network, and elsewhere in the UK equivalent re-
search infrastructure support is available. Participant
recruitment commenced in September 2018 and is
currently ongoing.
Participant eligibility is confirmed by the consultant
rheumatologist or a suitably qualified member of the
local research team with delegated responsibility from
the local Principal Investigator. Being an observational
study, cohort membership (i.e. whether the participant
joins the exposed or non-exposed groups) is not dictated
by the study protocol. Rather, it is determined by the
treatment decision of the rheumatology consultant, and
the patient, as per usual clinical practice.
Patients have at least 24 h to consider the information
in the participant information sheet and have the oppor-
tunity to ask questions. However, in line with the ethical
approval, if they indicate their willingness to participate
sooner, the taking of consent is not unduly delayed. Al-
though the majority of recruitment takes place face-to-
face, in exceptional circumstances participants may
complete the consent form and return it by post, provid-
ing that the local research nurse has had an opportunity
(either face-to-face or by telephone) to discuss the study
with the participant, and to answer any questions.
Data collection
During the development of the protocol and data col-
lection procedures, a consultation meeting was held
with representation from study investigators, patients,
and rheumatology consultants, to ensure that data
collection was relevant and comprehensive but
avoided duplication.
There are three main aspects of data collection.
(a) Clinical data
Data are recorded on a variety of clinical features,
either directly assessed by the research nurse or taken
retrospectively from the clinical notes, and includes
information regarding:
 Symptom onset and diagnosis;
 Joint disease;




Training was provided for research nurses prior to
commencement of the study. Various physical mea-
surements and laboratory test results are also taken.
A full list of clinical data collection items is shown in
Table 2. In addition, during follow-up, clinical staff
are asked to report any significant morbid events as
well as being asked to verify any such events notified
in patient diaries. Safety reporting is discussed below.
(b) Patient-reported data
At baseline and each follow-up point participants are
asked to complete a questionnaire. A full list of ques-
tionnaire instruments is shown in Table 3 and includes
questions on:
 General health;
 Functional status and impact of disease;
 Axial disease;
 Sleep and fatigue;
 Fibromyalgia;
 Mental health;
 Quality of life; and
 Employment status.
Table 1 Registry inclusion / exclusion criteria
Inclusion criteria Exclusion criteria
• Patients must … • Patients must not be …
• Have a clinical diagnosis of PsA; Unable to communicate in English;
• Meet CASPAR classification
criteria for PsA [7];
Deemed, in any other way, unable
to give informed consent;
• Be aged ≥16 years; Managed in paediatric
rheumatology services;
• Be either: Currently taking a bDMARD /
tsDMARD and not changing
treatment;
(a) Naïve to all bDMARD /
tsDMARD agents; or
Restarting a specific bDMARD /
tsDMARD agent that they have
received previouslya.
(b) Starting a bDMARD /
tsDMARD agent, approved for
the treatment of PsA in the
United Kingdom, having never
previously received that
particular druga.
aPatients are eligible if they are starting, or switching to, a biosimilar product
even if they have previously had (i) the originator product, and/or (ii) a
different biosimilar of the same product
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At baseline, participants are also asked for their prefer-
ence – postal, or online – which determines the ap-
proach for follow-up questionnaires.
(iii)Record linkage
Participants are asked for their consent to link their
study data to records held by NHS Digital (www.
digital.nhs.uk) for surveillance and notification of any
malignancy and/or mortality. In addition, for persons
recruited in Scotland data are linked to the Scottish
Morbidity Records held by National Health Services
Scotland (www.ndc.scot.nhs.uk), providing information
on inpatient episodes (including day case) and out-
patient attendances.
Follow-up
The study duration is 5 years in the first instance, and
all participants are followed up annually until the end of
the study, unless they withdraw. In addition, patients
commencing or switching to bDMARD or tsDMARD
therapy (either at recruitment, or during the course of
Table 2 Clinical data collection
Domain Items
General information Date of birth; gender; ethnicity; family history of PsA, psoriasis, and other relevant conditions.
Symptom onset and
diagnosis
Age at onset for joint disease, and skin disease, separately. Year that patient was first seen in rheumatology.
Joint disease 66/68 joint count.
Skin disease severity/
phenotype
Personal history of psoriasis. Current psoriasis: (a) phenotype: plaque, pustular (sub classified as palmoplantar pustulosis
or generalised pustular psoriasis); and (b) severity: body surface area affected, static physician global assessment.
Nail disease Presence of nail disease: nail matrix (e.g. pitting); nail bed (e.g. onycholysis); hyperkeratosis.
Dactylitis Current swelling of an entire digit; count of involved digits; history of dactylitis.
Enthesopathy Leeds Enthesitis Index [8].
Physical measurements Height; weight; waist circumference; and blood pressure.
Comorbidities Diabetes; ischaemic heart disease; hypertension; hyperlipidaemia; statin use; fatty liver disease; history of malignancy;
history of serious infection (infection resulting in hospitalisation, intravenous antibiotics); history of vasculitis; mental
health.
Novel therapy exposure Past history of all bDMARDs and tsDMARDs, including start date, dose, stop date and reason for discontinuation.
Other current and recent
therapies
History of conventional synthetic DMARDs, steroids, NSAIDs, PUVA, and systemic therapies for psoriasis. Data recorded
will comprise ever received therapy (yes/no); and, if applicable, calendar year.
A recent history (past 6 months) will also be taken, comprising start date, dose, and if applicable, stop date and reason
for discontinuation. Information will also be collected on any relevant concomitant therapies for comorbidities.
Spinal involvement/imaging Evidence of (a) juxta-articular new bone formation; (b) any erosion; and/or (c) sacroiliitis, by plain x-ray or MRI.
(NB: No new images will be taken specifically for the BSR-PsA.)
Laboratory markers Recent measure of inflammation (C-reactive protein) from the date of clinic visit date ±4 weeks.
Baseline only: rheumatoid factor and anti-citrullinated protein (anti-CCP) antibody, if available.
Table 3 Patient-reported data collection
Domain Items
General information Date of birth; education; smoking status, alcohol consumption; and physical activity.
General health PROMIS Scale v1.2 – Global Health [9]; and GRAPPA/OMERACT visual analogue scales (global, skin and joints) [10].
Axial disease Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [11].
Sleep, Fatigue and
Fibromyalgia
Jenkins Sleep Scale [12]; PROMIS Short Form – Fatigue 8a [9]; a general question on fatigue for comparability with
other studies (have you had problems with fatigue for more than 3 months?); plus, the 2011 modification of the ACR
preliminary diagnostic criteria for fibromyalgia [13].
Quality of life, and Impact of
disease
Generic instrument (EQ-5D-5L) [14]; plus, the PsA Quality of Life (PsAQoL) [15]; Dermatology Quality of Life Index
(DLQI) [16]; and Psoriatic Arthritis Impact of Disease (PsAID) questionnaire [17].
Functional status Health Assessment Questionnaire (HAQ) [18].
Mental health PROMIS Short Form – Anxiety 4a and Depression 4a questionnaires [9] plus, for comparability with other studies, a
question on anhedonia taken from the PHQ-9 [19].
Employment status Employment status, and the impact of PsA on employment: Work Productivity and Activity Impairment Questionnaire:
Specific Health Problem (WPAI: SHP) [20].
Jones et al. BMC Rheumatology            (2021) 5:19 Page 4 of 9
the study) will be followed up three and six months after
the start of therapy. Ordinarily, recruiting centres en-
deavour to ensure that each follow-up visit takes place
within ±28 days of the required time.1 Each follow-up
visit involves the collection of clinical and patient-
reported data, as per baseline. To decrease the burden
for recruiting centres, follow-up data collection is de-
signed to collect clinical data using a schedule that maps
to usual clinical practice insofar as possible, although
data collection can also take place at additional study-
specific visits.
During follow-up participants are asked to keep diaries
to record any hospital admissions, new drugs prescribed,
new referrals and/or pregnancy. In female participants,
in the event of a pregnancy, a supplementary question-
naire is sent, shortly after the expected date of delivery,
to collect information about the pregnancy, and preg-
nancy outcome. If a pregnancy is reported in a study
participant's partner, the questionnaire is sent to the
participant to pass on to their partner, with a separate
participant information sheet and consent form.
Health economics
Health care costs are collected from three main sources:
clinical records, patient diaries, and record linkage. Data
is collected on the frequency and type of NHS resource
use, such as hospital service use related to PsA and re-
flects the type and duration of inpatient stays, and the
type and frequency of outpatient visits. Costs include the
resource use associated with usual management of the
condition, together with costs associated with treatment
for serious adverse events. Quality of life data will be
collected from patient questionnaires, determined by the
EQ-5D-5L, which enables direct calculation of quality-
adjusted life years (QALYs).
Safety
Serious adverse events are defined as per the NIHR Clin-
ical Trials Toolkit (www.ct-toolkit.ac.uk/glossary), i.e.
any event that results in death, is life threatening, re-
quires hospitalisation or prolongation of existing hospi-
talisation, results in persistent or significant disability or
incapacity, or is a congenital anomaly or birth defect. In
addition, information on various events of special inter-
est is collected. These events, listed in Table 4, while not
necessarily constituting serious adverse events are of
particular clinical interest and warrant additional data
collection.
Biobank
Recent evidence suggests that different PsA phenotypes
may be determined by distinct genotypes and cytokine
responses [22]. This gives rise to specific testable hy-
potheses about treatment response among patients re-
ceiving therapeutic agents that ostensibly target single
pathways. Not available from the start of the study, but
beginning in 2021, we will collect and store urine,
serum, and plasma from a sub-sample of participants to
create a PsA biobank which will facilitate analyses at the
genomic, epigenetic, transcriptomic (including non-
coding RNA species) and metabolomics level.
Depending on local facilities, participants commencing
bsDMARD or tsDMARD therapy (either at recruitment,
or during follow-up) will be given the option of contrib-
uting to a biobank. Those who consent will be asked to
give blood and urine samples at their normal clinical
visit when commencing therapy, and at three-month
follow-up. Blood samples will be centrifuged in local fa-
cilities and plasma and serum extracted, and samples
will be transferred to the NHS Grampian Biorepository
where they will be stored for up to 10 years.
Statistics and data analysis
The study is designed to answer a series of questions re-
lated to natural history, outcome, treatment effectiveness
and co-morbidities and is therefore not powered on one
single analysis. Thus, the following are provided to give
an indicative example of study power. Available data
suggest that baseline risk of serious infection (infection
resulting in hospitalisation, intra-venous antibiotics, or
death) is around 20 events per 1000 person-years. To
detect a doubling in risk among PsA patients in the ex-
posed versus non-exposed groups we would require
1626 person-years of follow-up in each group. This
would provide 90% power at 5% significance and thus,
assuming a one-to-one ratio of patients, would require
723 PsA patients per group, each followed-up for an
average of 3 years.
The likelihood of achieving a positive treatment re-
sponse varies between products, and between outcome
measures. Based on three commonly used outcomes (the
ACR 20/50/70) and three commonly used agents (eta-
nercept/infliximab/adalimumab) the average treatment
response is approximately 40% [23]. Thus, assuming the
probability of achieving a positive treatment response is
0.40, a sample of this size would have 90% power to de-
tect a 50% increase in the probability of positive treat-
ment response associated with any exposure occurring
with a prevalence of 10%.
Initial analyses will consist of comparisons in baseline
characteristics between exposed and non-exposed
groups. Thereafter, because the study is designed to be
able to answer a number of different research questions,
1Commencing in March 2019, lockdown restrictions during the
COVID-19 pandemic meant that all participant recruitment, and al-
most all follow-up activity, was temporarily put on hold as face-to-face
activity was stopped, including non-urgent rheumatology consulta-
tions, and research nurses were co-opted back to clinical duties.
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the precise analysis will depend on the specific question
being asked. All analyses will require a detailed analysis
plan to be specified in advance. As indicative example:
differences in risk of serious infection between groups
will be examined using Cox-proportional hazards regres-
sion, allowing for between-group differences as potential
confounders and effect modifiers, and results will be
expressed as hazard ratios. Depending on the incidence
of the outcome events, more sophisticated models may
be possible – e.g. allowing the examination of time-
varying and/or age-specific risks. In addition, different
assumptions will be tested concerning specific risk win-
dows. Treatment success would be pre-specified – e.g.
achieving minimal disease activity twelve months after
commencing treatment [24] – and initial differences in
treatment outcome between exposed and non-exposed
groups would be examined with simple descriptive sta-
tistics. Thereafter, a logistic model would be fitted to es-
timate the odds ratio for minimal disease activity
between exposed/non-exposed patients. The model
would be statistically adjusted for other exposures and
patient characteristics associated with both the primary
exposure and the outcome, to control for potential
confounding.
The study will also provide several health economic
outputs: firstly, descriptive statistics in terms of costs
and quality of life for the entire registry population –
e.g. mean/median costs and EQ-5D-5L values per pa-
tient, for first and subsequent years of treatment; and
secondly, cost and QALY estimates per patient, control-
ling for patient differences in disease severity, number
and type of adverse events, and other important
Table 4 Events of special interest




Cerebrovascular accident Stroke and/or transient ischaemic attack.
Demyelination, optic neuritis –
Mental health ≥1 new prescription for depressive illness and/or≥ 1 new prescription for anxiety/nervousness.
Hepatitis B reactivation –
Hypersensitivity reaction Including skin eruptions and rashes, oedemas, anaphylactic reactions, and non-specific hypersensitivity – e.g.
Stevens Johnson syndrome, erythema multiforme, toxic epidermal necrosis. Life-threatening anaphylactoid
reactions including effects on blood pressure and respiratory effects as defined for anaphylaxis [21].
Inflammatory bowel disease Worsening of existing condition, or new onset.
Lymphoproliferative malignancy –
Malignancy, skin cancer, Bowen’s
disease
Including solid tumours, haematological tumours, melanoma, and non-melanoma skin cancers.
Major adverse cardiovascular events Including all incident myocardial infarctions and acute coronary syndrome. Sudden cardiac death, death due
to myocardial infarction, heart failure, stroke and other cardiovascular causes; myocardial infarction and non-
fatal stroke.
Pregnancy –
Psoriasis flare Worsening of existing psoriasis, or paradoxical psoriasis onset.
Pulmonary embolism –
Serious congestive heart failure –
Infection Serious infection – i.e. infection resulting in death, or is life threatening and/or requiring hospitalisation and/
or intravenous antibiotics. Systemic candida infection, and all recurrent candida and other fungal infections.
Serious hepatic dysfunction or failure –
Serious lower GI ulcer, bleed or
perforation
–
Serious lupus, or lupus-like illness –
Serious haemorrhage –
Suicide behaviours Including suicide ideation, suicide attempt, and suicide.
Tachyarrhythmia Including atrial fibrillation and flutter, supraventricular tachyarrhythmia and tachycardia, and ventricular
tachycardia, fibrillation, and flutter.
Tuberculosis –
Vasculitis Including renal and nodular vasculitis, polyarteritis nodosa, temporal arteritis, and all other vasculitis
conditions.
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potential confounding variables. Both costs and quality
of life data will be estimated using regression analysis, to
control for between patient differences in disease sever-
ity, number and type of serious adverse events, and other
important confounding variables. Direct estimation of
costs and quality of life using large-scale real-world pa-
tient data will allow us to produce more estimates of
cost-effectiveness. Such results will be able to inform in-
put parameters for future model-based economic evalua-
tions on the costs and effects of all new treatments for
PsA in the longer-term.
Research governance and study oversight
The study was externally peer reviewed as part of the
process of applying for funds, competitively, to the Brit-
ish Society for Rheumatology (BSR) and is registered on
the Open Science Framework (https://osf.io/jzs8n).
Favourable ethical opinion, which applies to all sites, was
obtained from the NHS West of Scotland Research Eth-
ics Committee 3 (reference: 18/WS/0126). Appropriate
NHS Research and Development approval is obtained
prior to the commencement of participant recruitment
at each site. The BSR is the legal sponsor for the study,
but delegates certain functions to the University of
Aberdeen.
The study is co-ordinated by a Study Management
Group consisting of the study investigators. A study co-
ordinator oversees the study and is accountable to the
Chief Investigator. A Data Monitoring Committee is
convened by the BSR. The register and data belong to
the BSR and oversight of the BSR-PsA is undertaken by
the BSR Registers Committee, consisting of BSR mem-
bers with various other co-opted representatives includ-
ing the Chief Investigator and Deputy Chief Investigator
of the BSR-PsA, patient organisation representatives,
and representatives from the BSR’s other registers. Sep-
arately, and reporting to the BSR Registers Committee, a
Data Monitoring Committee reviews reports of all ser-
ious adverse events and events of special interest.
Dissemination of findings
Dissemination of research output from the BSR-PsA will
comply with the policy as specified by the BSR’s Regis-
ters Committee. In addition, for output from the main
study investigators, lay summaries will be made available
online.
Discussion
Various extant registers across Europe collect some data
on PsA, including industry-sponsored and independent
registers, but the utility of these data is limited. The BSR
Biologics Register for Rheumatoid Arthritis (BSRBR-RA)
[25] initially included some patients with PsA although
with a predominant focus on rheumatoid arthritis failed
to adequately capture all relevant domains in PsA, espe-
cially skin disease and information on PsA-relevant out-
comes is limited (for example, by using DAS28, rather
than full 66/68 joint counts, and no assessment of axial
disease. Also, being outside their initial remit, when
numbers of patients with rheumatoid arthritis increased,
recruitment on PsA ceased. In other registers, such as
the British Association of Dermatologists Biologic and
Immunomodulators Register (BADBIR) [26], although
skin disease is well characterised, the full clinical features
of PsA are poorly documented (rheumatological assess-
ment is limited to the single question: Has the patient
received a diagnosis by a rheumatologist of psoriatic
arthritis?).
There is clear evidence, from randomised trials, that
bDMARDs and tsDMARDs are efficacious in the treat-
ment of PsA [23, 27, 28]. However, it has been shown
that certain clinical (e.g. oligoarthritis, those with comor-
bidities) and sociodemographic groups are likely to be
under-represented in clinical trial populations [29], and
this is likely to introduce potential bias to absolute effect
estimates. Indeed, data from the BSR Biologics Register
for Ankylosing Spondylitis indicate that in a real-world
patient population around half of patients respond to
TNF inhibition [6], compared to > 60% in the clinical tri-
als that led to the licensing of these agents. Also, there is
some evidence from a large claims database in the USA
that the majority of patients commencing TNF or IL-12/
23 inhibition had continued their index therapy within a
twelve-month period [30]. Long-term studies have the
opportunity to examine effectiveness of these agents in
real-world clinical populations and allows the examin-
ation of patient sub-groups that are seldom available in
clinical trials.
The broad inclusion criteria for the exposed group,
allowing patients commencing any bDMARD or
tsDMARD, is deliberately inclusive to reflect real-world
practice. The advent of biosimilars has brought a rapid
increase in the number of alternative bDMARDs avail-
able to the rheumatologist. Although manufactured to
be ‘similar’ to the originator product, and non-inferior in
terms of effectiveness and safety profile, biosimilar mole-
cules are not required to be tested in all indications and,
subsequently, may be licenced for use in PsA without
any clinical trial data in this patient group. Real-world
data therefore serve an important function in monitoring
effectiveness, safety, and cost-effectiveness of these new
products.
Previous economic modelling in PsA, on which man-
agement guidelines are based, have employed mapping
techniques to estimate quality of life as a function of dis-
ability and skin disease [31]. While these indirect
methods have some merit, where direct measurement of
health utility is lacking, there is some evidence that
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health utility scores obtained by extrapolating from dis-
ease activity and function differ markedly from those
calculated directly [32]. Large-scale real-world patient
data are required with estimates of QALYs determined
using directly collected health economic measures, as
well as the clinical tools used elsewhere. This will permit
robust estimates of cost-effectiveness and will either
challenge or confirm the indirect methods used in eco-
nomic modelling to date.
In summary, we have described the rationale and de-
sign for a prospective PsA registry to provide real-world
data with respect to the natural history of PsA and the
impact on the individual, including function, work, and
quality of life in the medium- to long-term; and the use
of effectiveness, cost-effectiveness, and predictors of
treatment response of bDMARD and tsDMARD thera-
peutics. Further, reserving biological samples against an
extensive clinical phenotyping database future-proofs the
BSR-PsA and facilitates biomarker evaluation and pre-
dictive modelling using various mathematical and in-
formatics solutions.
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